Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.

Meisel, Andreas; Annane, Djillali; Vu, Tuan; Mantegazza, Renato; Katsuno, Masahisa; Aguzzi, Rasha; Frick, Glen; Gault, Laura; Howard, James F

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.

Meisel, Andreas; Annane, Djillali; Vu, Tuan; Mantegazza, Renato; Katsuno, Masahisa; Aguzzi, Rasha; Frick, Glen; Gault, Laura; Howard, James F.

Afiliação

Meisel A; Charité Universitätsmedizin Berlin, Berlin, Germany. andreas.meisel@charite.de.
Annane D; Hôpital Raymond Poincaré, Garches, France.
Vu T; University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Mantegazza R; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Katsuno M; Nagoya University Graduate School of Medicine, Nagoya, Japan.
Aguzzi R; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Frick G; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Gault L; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Howard JF; The University of North Carolina, Chapel Hill, NC, USA.

J Neurol ; 270(8): 3862-3875, 2023 Aug.

Article em En | MEDLINE | ID: mdl-37103755

Assuntos

Atividades Cotidianas; Miastenia Gravis; Adulto; Humanos; Autoanticorpos; Miastenia Gravis/tratamento farmacológico; Receptores Colinérgicos; Resultado do Tratamento

Palavras-chave

Generalized myasthenia gravis; Long-term; Open-label; Ravulizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google